



COOL DOWN  
THE  
HIGH TIDE OF  
**ACID**



# ESOGRESS-IT

Esomeprazole Enteric Coated 40mg &  
Itopride Hydrochloride Sustained Release 150 mg Capsules

# ESOGRESS FAST-40

Esomeprazole 40 mg Tablets (With Sodium Bicarbonate as Buffer)

# ESOGRESS-20/40/D/L

Enteric Coated Tablets of Esomeprazole 20 mg and 40 mg/  
Esomeprazole Enteric Coated 40 mg with Domperidone 30 mg Sustained Release Capsules/  
Esomeprazole Enteric Coated 40 mg with Levosulpiride Sustained Release 75 mg Capsules

# ESOGRESS RANGE

## Background:

Gastroesophageal reflux disease (GERD) and Dyspepsia syndrome are prevalent in the community worldwide. In an individual, GERD and dyspepsia may occur simultaneously and therefore they are hardly discriminated. The global pooled prevalence of GERD is 13.98% and varied greatly according to region and country and the prevalence of dyspepsia is about 20-30%. PPI alone or in combination with a prokinetic agent is effective in improving the quality of life of patients suffering from diseases associated with acid reflux.

## Description:

- Esogress-IT contains Esomeprazole EC 40mg & Itopride Hydrochloride Sustained Release 150 mg Capsules
- Esogress Fast-40 contains Esomeprazole 40 mg Tablets (Film Coated Tablet) with Sodium Bicarbonate (buffer)
- Esogress-20/40 contains Esomeprazole 20/40 mg Gastro-resistant Tablets.
- Esogress-D contains Esomeprazole EC 40 mg with Domperidone 30 mg Sustained Release Capsules.
- Esogress-L contains Esomeprazole EC 40 mg with Levosulpiride Sustained Release 75 mg Capsules.

## Indication:

GERD | NAB (Nocturnal Acid Breakthrough) | Diabetic Gastroparesis | Functional Dyspepsia | Gastritis

## Mechanism of action:

- Esomeprazole is the S-enantiomer of omeprazole, specifically act as proton pump inhibitor, suppressing gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup> ATPase in the gastric parietal cell and blocking the final step in acid production, resulting in reduced gastric acidity.
- Domperidone has strong affinities for the D2 and D3 dopamine receptors. It facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure.
- Levosulpiride is a sulpiride isomer that exerts its prokinetic action through a dual mechanism, as a D2 dopamine receptor antagonist and as a serotonin 5HT<sub>4</sub> receptor agonist.
- Sodium Bicarbonate buffer protects against acid degradation of esomeprazole in addition to immediate antacid action.
- Itopride hydrochloride is a prokinetic agent. It has anticholinesterase (AChE) activity as well as dopamine D2 receptor antagonistic activity.

## Key features:

- Esomeprazole is effective in maintaining intragastric pH greater than equal to 4 compared to other PPI.<sup>1</sup>
- Domperidone is a unique gastroprokinetic and antiemetic drug, it does not cross the blood-brain barrier and therefore has fewer CNS side effects.<sup>2</sup>
- Levosulpiride has better tolerability than Cisapride and Metoclopramide and it is devoid of serious cardiovascular adverse effects.<sup>3</sup>
- Buffered esomeprazole achieves and maintains a pH of more than 6 within minutes of administration.<sup>4</sup>
- Itopride inhibits transient LES relaxations (TLESRs) without significantly affecting oesophageal peristaltic function or LES pressure.<sup>5</sup>

## Dosage:

Esogress-20/40/D/L/Fast-40/IT- Once daily or as prescribed by a registered medicinal professional.

## Presentation:




- Esogress-20/40 / Fast-40 available as a strip of 10 Tablets.
- Esogress-IT / D/L available as a strip of 10 Capsules.

### La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,  
S.G. Highway, Ahmedabad-380015, Gujarat, India.  
Phone: + 91-79-6616-8998 / 26936656 | Fax: +91-79-6616-8998  
E-mail: info@larenon.com | Web: www.larenon.com

### REFERENCES:

1. Therapeutics and Clinical Risk Management 2007;3( 4 ):653-663
2. Am J Gastroenterol 1999 May;94( 5 ):1230-4.
3. J Fam Med. 2015;2( 4 ): 1034.
4. Journal of Gastroenterology and Hepatology 25 (2010) 43-47 © 2009
5. Aliment Pharmacol Ther 2011; 33: 99-105

 I am: \_\_\_\_\_  
 Call me on: \_\_\_\_\_  
 Mail me at: \_\_\_\_\_